Dermata Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 13, 2025
DRMA$0.77+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
| For the six months ended June 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(4,004,680) | $(5,963,368) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 76,422 | 606,842 |
| Increase (decrease) in cash resulting from changes in: | ||
| Prepaid expenses and other current assets | 212,732 | 367,802 |
| Accounts payable | (356,816) | 360,253 |
| Accrued and other current liabilities | (552,205) | (201,936) |
| Total adjustments to reconcile net loss to net cash used in operations | (619,867) | 1,132,961 |
| Net cash used in operating activities | (4,624,547) | (4,830,407) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of Common Stock and warrants, net of issuance costs | 7,993,425 | 2,410,200 |
| Payment of prior period issuance costs | (50,495) | - |
| Issuance costs paid setting up ATM agreement | - | (70,000) |
| Proceeds from exercise of pre-funded warrants | 977 | - |
| Payment for fractional shares in reverse stock split | - | (828) |
| Net cash provided by financing activities | 7,943,907 | 2,339,372 |
| Net increase (decrease) in cash and cash equivalents | 3,319,360 | (2,491,035) |
| Cash and cash equivalents at beginning of period | 3,161,570 | 7,438,135 |
| Cash and cash equivalents at end of period | $6,480,930 | $4,947,100 |
| Non-cash financing activities: | ||
| March 2025 Warrant Inducement issuance costs in accounts payable | $12,987 | - |
| Issuance of abeyance shares | (4) | $(2) |
| May 2024 Warrant Reload issuance costs in accounts payable | - | $89,737 |
| Deferred financing costs included in accounts payable or accrued expenses | - | $46,755 |
| Supplemental disclosure: | ||
| Cash paid for taxes | $950 | $950 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.